Overview Dividends

(VTYX) Ventyx Biosciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92332V1070

Drug, Immune, Skin, Bowel, Psoriasis

VTYX EPS (Earnings per Share)

EPS (Earnings per Share) of VTYX over the last years for every Quarter: "2020-09-30": null, "2020-12-31": -0.9247, "2021-03-31": -0.9247, "2021-06-30": null, "2021-09-30": -3.17, "2021-12-31": -0.36, "2022-03-31": -0.45, "2022-06-30": -0.39, "2022-09-30": -0.59, "2022-12-31": -0.62, "2023-03-31": -0.68, "2023-06-30": -0.91, "2023-09-30": -0.92, "2023-12-31": -0.79, "2024-03-31": -0.62, "2024-06-30": -0.45, "2024-09-30": -0.5, "2024-12-31": -0.41, "2025-03-31": -0.39, "2025-06-30": -0.38,
EPS Growth (3Y CAGR): 19.61%
EPS Trend (3Y Correlation): 67.1%

VTYX Revenue

Revenue of VTYX over the last years for every Quarter: 2020-09-30: 0, 2020-12-31: 0, 2021-03-31: 0, 2021-06-30: 0, 2021-09-30: 0, 2021-12-31: 0, 2022-03-31: 0, 2022-06-30: 0, 2022-09-30: 0, 2022-12-31: 0, 2023-03-31: 0, 2023-06-30: 0, 2023-09-30: 0, 2023-12-31: 1.076, 2024-03-31: 0, 2024-06-30: 0, 2024-09-30: 0, 2024-12-31: 1.448, 2025-03-31: 0, 2025-06-30: 0,
Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): 22.1%

Description: VTYX Ventyx Biosciences

Ventyx Biosciences Inc (NASDAQ:VTYX) is a US-based pharmaceutical company. As a player in the pharmaceuticals industry, VTYX is subject to key economic drivers such as R&D pipeline progress, regulatory approvals, and market demand for its products.

The companys market capitalization stands at $200.38M USD, indicating a relatively small-cap stock with potential for significant price movements. The absence of a P/E ratio suggests that the company is currently unprofitable, which is common for biotech firms with promising pipelines but尚未 commercialized products.

To evaluate VTYXs performance, key performance indicators (KPIs) such as cash runway, R&D expenses as a percentage of market cap, and pipeline progress (e.g., number of assets in clinical trials, upcoming milestones) will be crucial. Investors should also monitor the companys burn rate and cash reserves to assess its ability to fund operations and achieve key milestones.

Given the industrys capital-intensive nature and the high-risk, high-reward profile of biotech investments, VTYXs stock price is likely to be influenced by news flow related to its pipeline, regulatory updates, and potential partnerships or collaborations. As such, investors should be prepared for potential volatility and closely monitor developments that could impact the companys valuation.

VTYX Stock Overview

Market Cap in USD 184m
Sub-Industry Pharmaceuticals
IPO / Inception 2021-10-21

VTYX Stock Ratings

Growth Rating -51.2%
Fundamental 36.0%
Dividend Rating -
Return 12m vs S&P 500 -17.3%
Analyst Rating 4.22 of 5

VTYX Dividends

Currently no dividends paid

VTYX Growth Ratios

Growth Correlation 3m 8.4%
Growth Correlation 12m 16.1%
Growth Correlation 5y -69.1%
CAGR 5y -60.63%
CAGR/Max DD 3y -0.62
CAGR/Mean DD 3y -0.65
Sharpe Ratio 12m -1.71
Alpha -8.35
Beta 0.829
Volatility 83.63%
Current Volume 545.2k
Average Volume 20d 442.7k
Stop Loss 2.1 (-8.7%)
Signal -1.17

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-119.0m TTM) > 0 and > 6% of Revenue (6% = 86.9k TTM)
FCFTA -0.57 (>2.0%) and ΔFCFTA -2.98pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 14.4k% (prev 22.2k%; Δ -7841 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.46 (>3.0%) and CFO -105.7m > Net Income -119.0m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 19.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (71.2m) change vs 12m ago 0.91% (target <= -2.0% for YES)
Gross Margin 31.77% (prev -29.37%; Δ 61.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.54% (prev 0.35%; Δ 0.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' -36.60

(A) 0.90 = (Total Current Assets 219.3m - Total Current Liabilities 11.5m) / Total Assets 230.0m
(B) -2.65 = Retained Earnings (Balance) -608.7m / Total Assets 230.0m
warn (B) unusual magnitude: -2.65 — check mapping/units
(C) -0.44 = EBIT TTM -117.4m / Avg Total Assets 269.6m
(D) -29.50 = Book Value of Equity -608.5m / Total Liabilities 20.6m
Total Rating: -36.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 36.02

1. Piotroski 1.0pt = -4.0
2. FCF Yield data missing
3. FCF Margin data missing
4. Debt/Equity 0.05 = 2.50
5. Debt/Ebitda -0.09 = -2.50
6. ROIC - WACC -58.28% = -12.50
7. RoE -48.89% = -2.50
8. Rev. Trend 22.13% = 1.66
9. EPS Trend 67.15% = 3.36

What is the price of VTYX shares?

As of September 16, 2025, the stock is trading at USD 2.30 with a total of 545,195 shares traded.
Over the past week, the price has changed by -3.36%, over one month by -18.73%, over three months by -9.45% and over the past year by -1.71%.

Is Ventyx Biosciences a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Ventyx Biosciences (NASDAQ:VTYX) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 36.02 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VTYX is around 1.50 USD . This means that VTYX is currently overvalued and has a potential downside of -34.78%.

Is VTYX a buy, sell or hold?

Ventyx Biosciences has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy VTYX.
  • Strong Buy: 5
  • Buy: 1
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the VTYX price?

Issuer Target Up/Down from current
Wallstreet Target Price 11.5 400%
Analysts Target Price 11.5 400%
ValueRay Target Price 1.7 -26.1%

Last update: 2025-09-05 05:07

VTYX Fundamental Data Overview

Market Cap USD = 184.0m (184.0m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 209.0m USD (Cash And Short Term Investments, last quarter)
P/B = 0.8821
Beta = 0.968
Revenue TTM = 1.45m USD
EBIT TTM = -117.4m USD
EBITDA TTM = -116.1m USD
Long Term Debt = 9.16m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.14m USD (from shortTermDebt, last quarter)
Debt = 10.3m USD (Calculated: Short Term 1.14m + Long Term 9.16m)
Net Debt = -22.0m USD (from netDebt column, last quarter)
Enterprise Value = -14.7m USD (184.0m + Debt 10.3m - CCE 209.0m)
Interest Coverage Ratio = unknown (Ebit TTM -117.4m / Interest Expense TTM 0.0)
FCF Yield = -892.7% (FCF TTM -131.1m / Enterprise Value -14.7m)
FCF Margin = -9055 % (FCF TTM -131.1m / Revenue TTM 1.45m)
Net Margin = -8220 % (Net Income TTM -119.0m / Revenue TTM 1.45m)
Gross Margin = 31.77% ((Revenue TTM 1.45m - Cost of Revenue TTM 988.0k) / Revenue TTM)
Tobins Q-Ratio = 0.02 (Enterprise Value -14.7m / Book Value Of Equity -608.5m)
Interest Expense / Debt = 35.17% (Interest Expense 3.62m / Debt 10.3m)
Taxrate = 21.0% (US default)
NOPAT = -117.4m (EBIT -117.4m, no tax applied on loss)
Current Ratio = 19.12 (Total Current Assets 219.3m / Total Current Liabilities 11.5m)
Debt / Equity = 0.05 (Debt 10.3m / last Quarter total Stockholder Equity 209.4m)
Debt / EBITDA = -0.09 (Net Debt -22.0m / EBITDA -116.1m)
Debt / FCF = -0.08 (Debt 10.3m / FCF TTM -131.1m)
Total Stockholder Equity = 243.5m (last 4 quarters mean)
RoA = -51.75% (Net Income -119.0m, Total Assets 230.0m )
RoE = -48.89% (Net Income TTM -119.0m / Total Stockholder Equity 243.5m)
RoCE = -46.47% (Ebit -117.4m / (Equity 243.5m + L.T.Debt 9.16m))
RoIC = -48.22% (NOPAT -117.4m / Invested Capital 243.5m)
WACC = 10.06% (E(184.0m)/V(194.3m) * Re(9.07%)) + (D(10.3m)/V(194.3m) * Rd(35.17%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.96%
Discount Rate = 9.07% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -131.1m)
EPS Correlation: 67.15 | EPS CAGR: 19.61% | SUE: 0.56 | # QB: False
Revenue Correlation: 22.13 | Revenue CAGR: 0.0%

Additional Sources for VTYX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle